帕金森病个性化治疗自适应 DBS 算法(ADAPT-PD)临床试验的传感数据和方法论

IF 6.7 1区 医学 Q1 NEUROSCIENCES
Scott Stanslaski, Rebekah L. S. Summers, Lisa Tonder, Ye Tan, Michelle Case, Robert S. Raike, Nathan Morelli, Todd M. Herrington, Martijn Beudel, Jill L. Ostrem, Simon Little, Leonardo Almeida, Adolfo Ramirez-Zamora, Alfonso Fasano, Travis Hassell, Kyle T. Mitchell, Elena Moro, Michal Gostkowski, Nagaraja Sarangmat, Helen Bronte-Stewart
{"title":"帕金森病个性化治疗自适应 DBS 算法(ADAPT-PD)临床试验的传感数据和方法论","authors":"Scott Stanslaski, Rebekah L. S. Summers, Lisa Tonder, Ye Tan, Michelle Case, Robert S. Raike, Nathan Morelli, Todd M. Herrington, Martijn Beudel, Jill L. Ostrem, Simon Little, Leonardo Almeida, Adolfo Ramirez-Zamora, Alfonso Fasano, Travis Hassell, Kyle T. Mitchell, Elena Moro, Michal Gostkowski, Nagaraja Sarangmat, Helen Bronte-Stewart","doi":"10.1038/s41531-024-00772-5","DOIUrl":null,"url":null,"abstract":"<p>Adaptive deep brain stimulation (aDBS) is an emerging advancement in DBS technology; however, local field potential (LFP) signal rate detection sufficient for aDBS algorithms and the methods to set-up aDBS have yet to be defined. Here we summarize sensing data and aDBS programming steps associated with the ongoing Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) pivotal trial (NCT04547712). Sixty-eight patients were enrolled with either subthalamic nucleus or globus pallidus internus DBS leads connected to a Medtronic Percept<sup>TM</sup> PC neurostimulator. During the enrollment and screening procedures, a LFP (8–30 Hz, ≥1.2 µVp) control signal was identified by clinicians in 84.8% of patients on medication (65% bilateral signal), and in 92% of patients off medication (78% bilateral signal). The ADAPT-PD trial sensing data indicate a high LFP signal presence in both on and off medication states of these patients, with bilateral signal in the majority, regardless of PD phenotype.</p>","PeriodicalId":19706,"journal":{"name":"NPJ Parkinson's Disease","volume":"6 1","pages":""},"PeriodicalIF":6.7000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sensing data and methodology from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) clinical trial\",\"authors\":\"Scott Stanslaski, Rebekah L. S. Summers, Lisa Tonder, Ye Tan, Michelle Case, Robert S. Raike, Nathan Morelli, Todd M. Herrington, Martijn Beudel, Jill L. Ostrem, Simon Little, Leonardo Almeida, Adolfo Ramirez-Zamora, Alfonso Fasano, Travis Hassell, Kyle T. Mitchell, Elena Moro, Michal Gostkowski, Nagaraja Sarangmat, Helen Bronte-Stewart\",\"doi\":\"10.1038/s41531-024-00772-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Adaptive deep brain stimulation (aDBS) is an emerging advancement in DBS technology; however, local field potential (LFP) signal rate detection sufficient for aDBS algorithms and the methods to set-up aDBS have yet to be defined. Here we summarize sensing data and aDBS programming steps associated with the ongoing Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) pivotal trial (NCT04547712). Sixty-eight patients were enrolled with either subthalamic nucleus or globus pallidus internus DBS leads connected to a Medtronic Percept<sup>TM</sup> PC neurostimulator. During the enrollment and screening procedures, a LFP (8–30 Hz, ≥1.2 µVp) control signal was identified by clinicians in 84.8% of patients on medication (65% bilateral signal), and in 92% of patients off medication (78% bilateral signal). The ADAPT-PD trial sensing data indicate a high LFP signal presence in both on and off medication states of these patients, with bilateral signal in the majority, regardless of PD phenotype.</p>\",\"PeriodicalId\":19706,\"journal\":{\"name\":\"NPJ Parkinson's Disease\",\"volume\":\"6 1\",\"pages\":\"\"},\"PeriodicalIF\":6.7000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NPJ Parkinson's Disease\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41531-024-00772-5\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Parkinson's Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41531-024-00772-5","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

自适应脑深部刺激(aDBS)是 DBS 技术的一个新兴进步;然而,足以用于 aDBS 算法的局部场电位(LFP)信号率检测以及设置 aDBS 的方法尚未确定。在此,我们总结了正在进行的帕金森病个性化治疗自适应 DBS 算法(ADAPT-PD)关键性试验(NCT04547712)的相关传感数据和 aDBS 编程步骤。68 名患者入选时使用了连接到美敦力 PerceptTM PC 神经刺激器的丘脑下核或苍白球内侧 DBS 导线。在入组和筛查过程中,84.8% 的服药患者(65% 为双侧信号)和 92% 的停药患者(78% 为双侧信号)的临床医生识别出了 LFP(8-30 Hz,≥1.2 µVp)控制信号。ADAPT-PD试验的感应数据表明,这些患者在服药和停药状态下均存在较高的LFP信号,且大多数患者为双侧信号,与帕金森病表型无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Sensing data and methodology from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) clinical trial

Sensing data and methodology from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) clinical trial

Adaptive deep brain stimulation (aDBS) is an emerging advancement in DBS technology; however, local field potential (LFP) signal rate detection sufficient for aDBS algorithms and the methods to set-up aDBS have yet to be defined. Here we summarize sensing data and aDBS programming steps associated with the ongoing Adaptive DBS Algorithm for Personalized Therapy in Parkinson’s Disease (ADAPT-PD) pivotal trial (NCT04547712). Sixty-eight patients were enrolled with either subthalamic nucleus or globus pallidus internus DBS leads connected to a Medtronic PerceptTM PC neurostimulator. During the enrollment and screening procedures, a LFP (8–30 Hz, ≥1.2 µVp) control signal was identified by clinicians in 84.8% of patients on medication (65% bilateral signal), and in 92% of patients off medication (78% bilateral signal). The ADAPT-PD trial sensing data indicate a high LFP signal presence in both on and off medication states of these patients, with bilateral signal in the majority, regardless of PD phenotype.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
NPJ Parkinson's Disease
NPJ Parkinson's Disease Medicine-Neurology (clinical)
CiteScore
9.80
自引率
5.70%
发文量
156
审稿时长
11 weeks
期刊介绍: npj Parkinson's Disease is a comprehensive open access journal that covers a wide range of research areas related to Parkinson's disease. It publishes original studies in basic science, translational research, and clinical investigations. The journal is dedicated to advancing our understanding of Parkinson's disease by exploring various aspects such as anatomy, etiology, genetics, cellular and molecular physiology, neurophysiology, epidemiology, and therapeutic development. By providing free and immediate access to the scientific and Parkinson's disease community, npj Parkinson's Disease promotes collaboration and knowledge sharing among researchers and healthcare professionals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信